Guangzhou Medical University reports discovery of oral proteasome inhibitor that blocks NLRP3 inflammasome activation
Sep. 19, 2022
Researchers from Guangzhou Medical University (GMU) described the discovery of a novel proteasome inhibitor NIC-0102, being developed as an anti-inflammatory therapeutic candidate.
